Nov 09, 2021 4:05 pm EST Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 02, 2021 4:05 pm EDT Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
Sep 24, 2021 7:00 am EDT Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Sep 22, 2021 4:05 pm EDT Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
Sep 07, 2021 9:00 am EDT Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 02, 2021 8:30 am EDT Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
Aug 12, 2021 4:01 pm EDT Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 05, 2021 9:00 am EDT Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
Aug 04, 2021 8:00 am EDT Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
Jul 27, 2021 8:00 am EDT Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors